Literature DB >> 30130450

A minimal physiologically based pharmacokinetic model to investigate FcRn-mediated monoclonal antibody salvage: Effects of Kon, Koff, endosome trafficking, and animal species.

Brian M Maas1, Yanguang Cao1.   

Abstract

Manipulation of binding affinity between monoclonal antibodies (mAbs) and the neonatal Fc receptor (FcRn) has been leveraged to extend mAb half-life; however, the steps required for success remain ambiguous and experimental observations are inconsistent. Recent models have considered the time course of endosomal transit a major contributor to the relationship between FcRn affinity and antibody half-life. Our objective was to develop a minimal physiologically based pharmacokinetic model to explain how changes in IgG-FcRn association rate constant (Kon), dissociation rate constant (Koff), and endosomal transit time [T(w)] translate to improved IgG clearance across mice, monkeys and humans. By simulating mAb clearance across physiological values of Kon, Koff, and T(w), we found that lowering Koff improves clearance only until the dissociation half-life reaches endosomal transit time. In contrast, Kon influenced clearance independently of T(w).The model was then applied to fit 66 mAb plasma profiles across species digitized from the literature, and clearance of mAb (CLIgG) and vascular fluid-phase endocytosis rate (CLup) were estimated. We found that CLIgG scaled well with body weight (allometric exponent of 0.90). After accounting for mAbs with significant FcRn binding at physiological pH, CLup was allometrically scalable (exponent 0.72). For the antibodies surveyed, Kon was more highly correlated with CLIgG across all species. The relationship between Koff and KD with CLIgG was largely inconsistent. Taken together, this model provides a parsimonious approach to evaluate endosomal transit kinetics using only mAb plasma concentrations. These findings reinforce the idea that endosomal transit kinetics should be considered when modeling FcRn salvage.

Entities:  

Keywords:  FcRn salvage; clearance; endosomal transit; mPBPK; therapeutic antibody

Mesh:

Substances:

Year:  2018        PMID: 30130450      PMCID: PMC6284604          DOI: 10.1080/19420862.2018.1506648

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  31 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

2.  Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn.

Authors:  Raimund J Ober; Cruz Martinez; Carlos Vaccaro; Jinchun Zhou; E Sally Ward
Journal:  J Immunol       Date:  2004-02-15       Impact factor: 5.422

3.  pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

Authors:  M Jack Borrok; Yanli Wu; Nurten Beyaz; Xiang-Qing Yu; Vaheh Oganesyan; William F Dall'Acqua; Ping Tsui
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

Review 4.  Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know.

Authors:  Ian N Foltz; Margaret Karow; Scott M Wasserman
Journal:  Circulation       Date:  2013-06-04       Impact factor: 29.690

Review 5.  Application of FcRn binding assays to guide mAb development.

Authors:  Amita Datta-Mannan; Victor J Wroblewski
Journal:  Drug Metab Dispos       Date:  2014-07-14       Impact factor: 3.922

6.  A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

7.  Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.

Authors:  Takuo Suzuki; Akiko Ishii-Watabe; Minoru Tada; Tetsu Kobayashi; Toshie Kanayasu-Toyoda; Toru Kawanishi; Teruhide Yamaguchi
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

8.  Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.

Authors:  Yik Andy Yeung; Maya K Leabman; Jonathan S Marvin; Julia Qiu; Camellia W Adams; Samantha Lien; Melissa A Starovasnik; Henry B Lowman
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

9.  Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.

Authors:  Amit Garg; Joseph P Balthasar
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-07-18       Impact factor: 2.745

10.  Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.

Authors:  Chee M Ng; Paul J Fielder; Jin Jin; Rong Deng
Journal:  AAPS J       Date:  2016-04-13       Impact factor: 4.009

View more
  8 in total

1.  Pharmacokinetics and pharmacodynamics of therapeutic antibodies in tumors and tumor-draining lymph nodes.

Authors:  Eric Salgado; Yanguang Cao
Journal:  Math Biosci Eng       Date:  2020-11-19       Impact factor: 2.080

Review 2.  Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.

Authors:  Patrick M Glassman; Joseph P Balthasar
Journal:  Drug Metab Pharmacokinet       Date:  2018-11-22       Impact factor: 3.614

3.  Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis.

Authors:  Thomas E Kraft; Wolfgang F Richter; Thomas Emrich; Alexander Knaupp; Michaela Schuster; Andreas Wolfert; Hubert Kettenberger
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

4.  Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases.

Authors:  Peter Bloomingdale; Suruchi Bakshi; Christian Maass; Eline van Maanen; Cesar Pichardo-Almarza; Daniela Bumbaca Yadav; Piet van der Graaf; Nitin Mehrotra
Journal:  J Pharmacokinet Pharmacodyn       Date:  2021-08-10       Impact factor: 2.745

5.  A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph Nodes.

Authors:  Eric Salgado; Yanguang Cao
Journal:  Antibodies (Basel)       Date:  2022-04-14

Review 6.  Modeling Pharmacokinetics and Pharmacodynamics of Therapeutic Antibodies: Progress, Challenges, and Future Directions.

Authors:  Yu Tang; Yanguang Cao
Journal:  Pharmaceutics       Date:  2021-03-21       Impact factor: 6.321

Review 7.  In Translation: FcRn across the Therapeutic Spectrum.

Authors:  Timothy Qi; Yanguang Cao
Journal:  Int J Mol Sci       Date:  2021-03-17       Impact factor: 5.923

Review 8.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.